Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EURTAC: Erlotinib vs Chemotherapy in EGFR-Mutated NSCLC
NCT00446225Phase 3Completed
- Sponsor
- Fundación GECP
- Start
- Feb 2007
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of erlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Fundación GECP. Primary endpoint: Progression-Free Survival at 24 months. Started Feb 2007; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00446225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00446225.